<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ900927-0031</DOCNO><DOCID>900927-0031.</DOCID><HL>   Technology Brief -- Genetics Institute Inc.:   Company Gets U.S. Patent   For Interleukin-3 Products</HL><DATE>09/27/90</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   GENI</CO><IN>MEDICAL AND BIOTECHNOLOGY (MTC)</IN><LP>   Genetics Institute Inc., Cambridge, Mass., said it wasawarded a U.S. patent covering human Interleukin-3 typeproducts.   The patent covers proteins produced using all or part ofthe Interleukin-3 DNA sequence. Last November, GeneticsInstitute received patents on the process of makingInterleukin-3 using recombinant DNA technology. Interleukin-3type is a blood cell growth factor that stimulates certaincells in the body's host defense system. The company believesit may be useful in treating blood cell deficienciesassociated with cancer treatment, bone marrow transplantationand certain other blood disorders. Sandoz Ltd. has licensedcertain manufacturing and marketing rights for Interleukin-3from Genetics Institute and has begun clinical trials withthe drug.</LP><TEXT/></DOC>